The Complete List and Analysis of the Best Pharmaceutical Companies for Cardiovascular in 2017
The global cardiovascular therapeutics market in 2017 was estimated at USD 129 billion and projected to grow at CAGR of 2.3% to reach USD 141.38 billion by 2021. The top 10 cardiovascular drugs accounted for revenue of USD 11.55 billion in 2017. AstraZeneca/Shionogi /Chiesi, dominates the cardiovascular market, with its best-selling product, Crestor/Provisacor.
Sources: SEC filings, companies websites, and annual reports.Top 10 Pharmaceutical Companies 2018 – Cardiovascular last edit: 2018-07-24T18:30:13+00:00 da